This new therapy gives me another option in the fight against my cancer, said the 35-year-old mother of three who travels to San Antonio for treatment with her husband and children. Before coming to CTRC, I had already been through one chemotherapy cycle for this disease, and I got the impression that no one really knew what to do with me or how to treat my cancer. REOLYSIN was a less toxic option for me.
"We are delighted, but not surprised, with the rate of accrual at the CTRC Institute for Drug Development, said Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. As an evolving oncology company, the placement of Oncolytics very innovative and sophisticated studies is of critical importance and we are delighted to have the CTRC Institute for Drug Development as our collaborator. This study is expected to yield information that will guide the late stage clinical development program for REOLYSIN.
REOLYSIN demonstrated success against tumors during earlier phases of scientific testing. This study (REO 014) is a Phase II, open-label, single agent study with the primary objective of measuring tumor responses and the duration of those responses, and of describing any evidence of anti-tumor activity. REOLYSIN will be given intravenously to patients for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.